Helpful Resource
July is Sarcoma Cancer Awareness Month

We've treated 1,269 cases of varying types of sarcomas, representing over 40% of our patients.

Together, we are closing the knowledge gap by learning with every sarcoma patient. The more we know, the better we can leverage all available interventions.

In honor of our sarcoma patients, we've compiled a select sample of sarcoma case studies to share with you (one each week). We hope you find each helpful to your personal decision-making process should your dog ever be diagnosed with cancer.

Telangiectatic Osteosarcoma Case Study: Scout
by: Dr. Dorothy Jackson Girimonte

History and Initial Therapy
Scout Shiratori, an almost 9-year-old male neutered Golden Retriever mix as seen on June 3, 2020 for a mass found under his right forelimb. Physical examination and radiographs confirmed a mass possibly associated with the fifth rib.

Cytology was diagnostic for a sarcoma, likely osteosarcoma or chondrosarcoma. CT scan confirmed the osteolytic lesion on the distal aspect of the right fifth rib, and there was no evidence of pulmonary metastasis.

Scout had surgery to remove the mass and associated rib. Histopathology was diagnostic for a telangiectactic osteosarcoma removed with clean margins.

Following surgery, Scout completed a course of Carboplatin on August 31, 2020. At that visit, a metastic pulmonary nodule was found on radiographs.

He then received the Yale vaccine and was started on metronomic cyclophosphanide on September 21, 2020. At that time, tissue was submitted for FidoCure analysis.

FidoCure Analysis
Genomic analysis of Scout’s tumor revealed 8 mutations, 4 of which were considered actionable. These alterations included CDK4, P53 (2), and SETD2. CDK4 is the gene encoding cyclin-dependent kinase 4. CDKs are kinases that regulate progression through the cell cycle.

CDK4 is specifically involved in the transition from G1 to S phase. Loss of G1 control in the cell cycle appears to be an important contributor to tumorigenesis.

TP53 encodes a protein called tumor protein p53 which has become one of the most well published tumor suppressor genes in both human and canine cancer. This protein helps to regulate cell growth and damaged cells by controlling signals for pausing the cell cycle and cell death.

SETD2 is a gene that encodes a lysine methyltransferase which has been described for tumor suppressor properties in human cancer literature. Mutations in SETD2 contribute to epigenetic regulation and interact with or modify the activity of histone deacetylases (HDAC).

With a combination approach that included FidoCure® therapy, Scout has lived for 1.5 years after his initial diagnosis of telangiectatic osteosarcoma.

If your dog is diagnosed with cancer, we want you to be aware of all the options, including ours!

Be sure to talk to your vet about FidoCure as they may not yet be aware of this option.
Purrch communities
Connect with pet parents and experts around important pet-related topics
  • Canines with Cancer Community
    Canines with Cancer
    Expert: FidoCure

    A compassionate group of dog parents who are either dealing with, or have overcome, a pet cancer diagnosis.

    Have a dog that’s been diagnosed with cancer?

    Join Us
  • Tummy Troubles Community
    Tummy Troubles
    Expert: DIG Labs

    A welcoming community of pet parents who want to help their dogs overcome sensitive stomachs and digestive issues

    Have a dog that suffers from tummy troubles?

    Join Us